Related Experiment Video
Updated: Jul 5, 2026
10:58
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
Published on: July 18, 2016
Topotecan for ovarian cancer
The Cochrane Database of Systematic Reviews
|April 22, 2008
Summary
Topotecan shows similar effectiveness to paclitaxel and pegylated liposomal doxorubicin for ovarian cancer treatment, but with different side effect profiles. Further high-quality trials are needed to determine optimal topotecan regimens.
Area of Science:
- Oncology
- Pharmacology
Background:
- Topotecan is a chemotherapeutic agent used for ovarian cancer.
- Systematic reviews on topotecan's efficacy and safety in ovarian cancer are lacking.
Purpose of the Study:
- To systematically evaluate the effectiveness and safety of topotecan in treating ovarian cancer.
Main Methods:
- Searched multiple databases including CENTRAL, MEDLINE, EMBASE, EORTC, and CBM.
- Included randomized controlled trials (RCTs) comparing topotecan with other treatments.
- Two reviewers independently extracted and analyzed data.
Main Results:
- Six poor-quality RCTs with 1323 participants were included.
- Topotecan demonstrated comparable progression-free survival to pegylated liposomal doxorubicin (PLD) but was more hematologically toxic than paclitaxel or PLD.
- Topotecan showed improved progression delay compared to paclitaxel, with a 21-day cycle being more effective and toxic than a 42-day cycle.
Conclusions:
- Topotecan exhibits similar effectiveness to paclitaxel and PLD, but with distinct side effect profiles.
- Larger, well-designed RCTs are necessary to establish optimal topotecan treatment regimens for ovarian cancer.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...